{
Danish Krone

Currency

}
novo nordisk faces stock plunge after disappointing results for obesity drug
Novo Nordisk's shares plummeted over 21% following disappointing results from the Phase 3 trial of its obesity drug CagriSema, which achieved a 22.7% average weight reduction, falling short of the expected 25%. Analysts have reacted with downgrades, citing safety concerns and underperformance compared to competitors. Despite achieving primary study objectives, the market's response reflects significant investor disappointment.
aktiencheck.de
Danish Krone Catalent, Inc. Novo Nordisk A/S Eli Lilly and Company DNK Florent Cespedes Emmanuel Papadakis Jo Walton Peter Welford Show more
Healthcare, Market Report
15:35 20.12.2024
ubs maintains neutral rating on novo nordisk amid disappointing weight loss data
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1,100 Danish crowns. Analyst Jo Walton highlighted disappointing results for the weight loss drug Cagrisema, which showed a 20.4% reduction, falling short of the expected 25%. Future focus may shift towards availability, tolerability, and convenience of oral administration rather than efficacy.
boerse.de
Danish Krone Novo Nordisk A/S Eli Lilly and Company DNK Jo Walton Show more
Healthcare, Market Report
15:17 20.12.2024
ubs lowers novonesis target price to dkk 455 maintains neutral stance
UBS has lowered the target price for Novonesis A/S to DKK 455, maintaining a neutral stance on the company. As a leading producer of enzymes and micro-organisms, Novonesis generates sales primarily from the cleaning and household products industry (28.5%) and bioenergy (24.8%), with significant contributions from food and human health (22.1%) and agriculture (11.8%). Geographically, North America accounts for 33.9% of sales, followed by Europe-Middle East-Africa (33.5%) and Asia-Pacific (18.5%).
Zonebourse
Danish Krone Novonesis A/S DNK Show more
Finance & Economy, Market Report
09:59 18.12.2024
UBS Adjusts Novonesis Target Price Amid Diverse Global Market Presence
UBS has lowered its target price for Novonesis A/S to DKK 455 while maintaining a neutral rating. The company, a leader in enzyme and microorganism production, generates net sales primarily from cleaning products (28.5%), bioenergy (24.8%), and the food industry (22.1%), with significant revenue from North America (33.9%) and Europe/Middle East/Africa (33.5%).
MarketScreener
Danish Krone Novonesis A/S DNK Show more
Finance & Economy, Market Report
09:59 18.12.2024
ubs lowers novonesis target price while maintaining neutral outlook
UBS has lowered its target price for Novonesis A/S to DKK 455 while maintaining a neutral rating. The company, a leader in enzyme and microorganism production, generates net sales primarily from cleaning products (28.5%), bioenergy (24.8%), and the food industry (22.1%), with significant revenue from North America (33.9%) and Europe/Middle East/Africa (33.5%).
MarketScreener
Danish Krone Novonesis A/S DNK Show more
Technology & Innovation, Market Report
09:59 18.12.2024
UBS Lowers Lundbeck Target Price Amid Ongoing Pharmaceutical Developments
UBS has reduced its target price for H Lundbeck A/S to DKK 45 from DKK 49, maintaining a neutral stance on the company. Lundbeck, based in Denmark, specializes in pharmaceuticals for brain diseases, with a portfolio that includes treatments for conditions such as depression, Alzheimer's, and Parkinson's.
MarketScreener
Danish Krone DNK Show more
Healthcare, Market Report
09:55 17.12.2024
UBS Cuts Lundbeck Target Price to DKK 45 Maintains Neutral Rating
UBS has reduced its target price for Lundbeck to DKK 45 from DKK 49 while maintaining a neutral stance on the company. Lundbeck A/S, a Danish pharmaceutical firm, specializes in developing treatments for brain disorders, including Alzheimer's, depression, and Parkinson's disease, with a diverse product portfolio.
Zonebourse
Danish Krone DNK Show more
Healthcare, Market Report
09:55 17.12.2024
UBS Maintains Neutral Rating for Novo Nordisk with Target Price of 1100 Kroner
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Analyst Jo Walton noted a slight increase in first-time prescriptions for weight-loss drugs in the US, based on data up to December 6.
boerse.de
United States Dollar Danish Krone Novo Nordisk A/S DNK Jo Walton
Healthcare, Market Report
15:24 16.12.2024
ubs lowers carlsberg target price amid strong global beer sales
UBS has reduced its target price for Carlsberg A/S to DKK 800 from DKK 870, maintaining a neutral stance on the company. Carlsberg, a leading global beer producer, sold 101 million hectoliters of beer in 2023, primarily under the Carlsberg and Tuborg brands, and also produced 24.1 million hectoliters of non-alcoholic beverages in 2022. The company operates 71 breweries across various regions, with net sales distributed as follows: Western Europe (50.7%), Asia (31.7%), and Eastern/Central Europe (17.6%).
MarketScreener
Danish Krone Carlsberg A/S GBR POL DEU CHN DNK Show more
Finance & Economy, Market Report
10:04 12.12.2024
UBS Adjusts Carlsberg Target Price Amidst Global Beer Market Dynamics
UBS has reduced its target price for Carlsberg A/S to DKK 800 from DKK 870 while maintaining a neutral stance. The company is a major global beer producer, with 101 million hectoliters sold in 2023, primarily under the Carlsberg and Tuborg brands, and operates 71 breweries across various regions. Its net sales are predominantly from Western Europe (50.7%), followed by Asia (31.7%) and Eastern/Central Europe (17.6%).
MarketScreener
Danish Krone Carlsberg A/S GBR DNK DEU POL CHN Show more
TradFi, Market Report
10:04 12.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Central Bank Actions Banking Regulations Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Mergers & Acquisitions Cryptocurrency & Blockchain Regulations Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK NGA FIN COL AUT VGB LIE TUR
Companies:
Credit Suisse Real Estate Fund Siat BlackRock, Inc. Coinbase Global, Inc. Solana USD Ethereum USD Apple Inc. Ripples USD Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.